Cellectis Announces Annual Shareholders General Meeting for June 2026

On May 20, 2026, Cellectis S.A., a clinical-stage biotechnology company specializing in gene-editing and allogeneic CAR T immunotherapies, announced that it will hold its Annual Shareholders General Meeting on June 25, 2026. The meeting is scheduled for 2:30 p.m. CET at the Biopark auditorium in Paris, France. The company has made the notice of the meeting available on its investor relations website. This filing serves as a standard administrative update regarding corporate governance and shareholder engagement. Cellectis continues to focus on its pioneering gene-editing platform to develop off-the-shelf, ready-to-use gene-edited CAR T-cells for oncology and other therapeutic indications. No updates regarding clinical trial data, regulatory milestones, or financial results were included in this specific announcement.